Quick Answer
Larimar Therapeutics, Inc. reported Earnings Per Share Diluted of $1.32 (loss) per share for the year ending 2024.
- Larimar Therapeutics, Inc. showed a decrease of -57.1% in Earnings Per Share Diluted from 2023 to 2024.
- This data is from Larimar Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $1.21 (loss) per share | Q3 2020: $0.64 (loss) per share | Q1 2021: $0.76 (loss) per share | Q2 2021: $0.79 (loss) per share | Q3 2021: $0.92 (loss) per share | Q1 2022: $0.49 (loss) per share | Q2 2022: $0.47 (loss) per share | Q3 2022: $0.37 (loss) per share | Q1 2023: $0.15 (loss) per share | Q2 2023: $0.19 (loss) per share | Q3 2023: $0.21 (loss) per share | Q1 2024: $0.27 (loss) per share | Q2 2024: $0.34 (loss) per share | Q3 2024: $0.24 (loss) per share | Q1 2025: $0.46 (loss) per share | Q2 2025: $0.41 (loss) per share | Q3 2025: $0.61 (loss) per share.
- Over the full 5 years of available data (2020 to 2024), Larimar Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 63.0%.
- Historical annual values: Fiscal year 2024: $1.32 (loss) per share | Fiscal year 2023: $0.84 (loss) per share | Fiscal year 2022: $1.37 (loss) per share | Fiscal year 2021: $2.95 (loss) per share | Fiscal year 2020: $3.57 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: